Inhibitory effects of the new anti-inflammatory agent, IS-741, on spontaneous colitis in HLA-B27/β2-microglobulin transgenic rats

Journal of Gastroenterology and Hepatology (Australia)

Volumn 17, Issue 8, 2002, Pages 854-860

  Makino, Jin ^a   Andoh, Akira ^a   Hata, Kazunori ^a   Yotsuya, Shuichi ^b   Shikama, Hiroshi ^b   Imamura, Masashi ^b   Fujiyama, Yoshihide ^a   Bamba, Tadao ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b ISHIHARA SANGYO KAISHA LTD   (Japan)

Author keywords

Experimental colitis; Inflammation; Ulcerative colitis

Indexed keywords

BETA 2 MICROGLOBULIN; CD3 ANTIGEN; CYTOKINE INDUCED NEUTROPHIL CHEMOATTRACTANT; HLA B27 ANTIGEN; MYELOPEROXIDASE; N (2 ETHYLSULFONYLAMINO 5 TRIFLUOROMETHYL 3 PYRIDYL)CYCLOHEXANECARBOXAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ADHESION; CELL INFILTRATION; COLITIS; COLON MUCOSA; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIUM CELL; ENTERITIS; ENZYME ACTIVITY; ENZYME ASSAY; HISTOPATHOLOGY; INFLAMMATORY CELL; MALE; NERVE; NEUTROPHIL; NONHUMAN; ORGAN WEIGHT; PRIORITY JOURNAL; PROTEIN DETERMINATION; RAT; SCORING SYSTEM; SUBMUCOSA; T LYMPHOCYTE; TRANSGENIC ANIMAL;

EID: 0036379717     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.2002.02815.x     Document Type: Article

References (29)

1. Arseneau KO, Pazarro TT, Cominelli F. Discovering the cause of inflammatory bowel disease: Lessons from animal model. Curr. Opin. Gastroenterol. 2000; 16: 310-17.
2. Elson CO, Sartor RB, Tennyson GS, Riddell RH. Experimental models of inflammatory bowel disease. Gastroenterology 1995; 109: 1344-67.
3. Inman RD, Scofield RH. Etiopathogenesis of ankylosing spondylitis and reactive arthritis. Curr. Opin. Rheumatol. 1994; 6: 360-70.
4. 2m: An animal model of HLA-B27-associated human disorders. Cell 1990; 63: 1099-112.
5. Taurog JD, Richardson JA, Croft JT et al. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J. Exp. Med. 1994; 180: 2359-64.
6. Taurog JD, Maika SD, Simmons WA, Breban M, Hammer RE. Susceptibility to inflammatory disease in HLA-B27 transgenic rat lines correlates with the level of B27 expression. J. Immunol. 1993; 150: 4168-78.
7. 2 microglobulin transgenic rats. J. Clin. Invest. 1996; 98: 945-53.
8. Rath HC, Wilson KH, Sartor RB. Differential induction of colitis and gastritis in HLA-B27 transgenic rats selectively colonized with Bacteroides vulgatus or Escherichia coli. Infect. Immun. 1999; 67: 2969-74.
9. Rath HC, Ikeda JS, Linde HJ, Schölmerich J, Wilson KH, Sartor RB. Varying cecal bacterial loads influences colitis and gastritis in HLA-B27 transgenic rats. Gastroenterology 1999; 116: 310-19.
10. Yotsuya S, Shikama H, Nakano I, Sakai K, Kato M, Sugi H. A novel synthetic anti-acute pancreatitis agent, IS-741. Digestion 1999; 60: 34-9.
11. Yamaguchi Y, Okabe K, Liang J, Matsumura F, Akizuki E, Mitsuda T. Novel carboxamide derivative IS-741 reduces neutrophil chemoattractant production by bronchoalveolar macrophages in rats with cerulein-induced pancreatitis complicated by sepsis. Digestion 1999; 60: 52-6.
12. Liang J, Yamaguchi Y, Matsumura F, Okabe K, Akizuki E. Novel carboxamide derivative (IS-741) attenuates lung injury in rats with cerulein-induced pancreatitis complicated by endotoxemia. Dig. Dis. Sci. 1999; 44: 341-9.
13. Shikama H, Yotsuya S, Satake S, Sugi H, Kato M. Effect of IS-741 on cell adhesion between human umbilical vein endothelial cells and HL-60 cells. Biol. Pharm. Bull. 1999; 22: 127-31.
14. Yotsuya S, Shikama H, Imamura M. Efficacy of the inflammatory cell infiltration inhibitor IS-741 on colitis induced by dextran sulfate sodium in the rat. Jpn. J. Pharmacol. 2001; 87: 151-7.
15. Krawisz JE, Sharon P, Stenson WF. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology 1984; 87: 1344-50.
16. Nakamura S, Ohtani H, Watanhabe Y et al. In situ expression of the cell adhesion molecules in inflammatory bowel disease: Evidence of immunologic activation of vascular endothelial cells. Lab. Invest. 1993; 69: 77-85.
17. Oshitani N, Campbell A, Bloom S, Kitano A, Kobayashi K, Jewell DP. Adhesion molecule expression on vascular endothelial and nitroblue terazolium reducing activity in human colonic mucosa. Scand. J. Gastroenterol. 1995; 30: 915-20.
18. Koizumi M, King N, Lobb R, Benjamin C, Podolsky DK. Expression of vascular adhesion molecules in inflammatory bowel disease. Gastroenterogy 1992; 103: 840-7.
19. Strober W, Fuss IJ, Ehrhardt RO, Neurath M, Boirivant M, Ludviksson BR. Mucosal immunoregulation and inflammatory bowel disease: New insights from murine models of inflammation. Scand. J. Immunol. 1998; 48: 453-8.
20. Strober W, Fuss IJ. Experimental models of inflammation and their relation to human inflammatory bowel disease. In: Domschke W, Stoll R, Brasitus TA, Kagnoff MF, eds. Falk Symposium 110. Intestinal Mucosa and its Diseases. Pathophysiology and Clinics. Dordrecht: Kluwer Academic Publishers, 1999; 457-70.
21. Kucharzik T, Lügering N, Stoll R, Domschke W. Regulation of inflammatory response by suppressor cytokines. In: Domschke W, Stoll R, Brasitus TA, Kagnoff MF, eds. Falk Symposium 110. Intestinal Mucosa and its Diseases. Pathophysiology and Clinics. Dordrecht: Kluwer Academic Publishers, 1999; 471-82.
22. Levine AD, Fiocchi C. Cytokines: Opportunities for therapeutic intervention. In: Gaginella TS, Guglietta A, eds. Drug Development: Molecular Targets for Gastrointestinal Diseases. Totowa: Human Press, 1999; 61-87.
23. Parronchi P, Romagnani P, Annunziato F et al. Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease. Am. J. Pathol. 1997; 150: 823-32.
24. Lugering N, Kucharzik T, Stein H, Winde G, Lugering A, Hasilik A. IL-10 synergizes with IL-4 and IL-13 in inhibiting lysosomal enzyme secretion by human monocytes and lamina propria mononuclear cells from patients with inflammatory bowel disease. Dig. Dis. Sci. 1998;43: 706-14.
25. Kucharzik T, Lugering N, Adof M, Domschke W, Stoll R. Synergistic effect of immunoregulatory cytokines on peripheral blood monocytes from patients with inflammatory bowel disease. Dig. Dis. Sci. 1997; 42: 805-12.
26. Sutterwala ES, Noel GJ, Salgame P, Mosser DM. Reversal of proinflammatory responses by ligating the macrophage Fcg receptor type I. J. Exp. Med. 1998; 188: 217-22.
27. + lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J. Immunol. 1996; 157: 1261-70.
28. Inoue S, Matsumoto T, Iida M, et al. Characterization of cytokine expression in the rectal mucosa of ulcerative colitis: Correlation with disease activity. Am. J. Gastroenterol. 1999; 94: 2441-6.
29. Hata K, Andoh A, Sato H, et al. Sequential changes in luminal microflora and mucosal cytokine expression during development of colitis in HLA-B27/beta2-microglobulin transgenic rats. Scand. J. Gastroenterol. 2001; 36: 1185-92.